The UK Space Agency Collaborates to Revolutionize Pharmaceutical Manufacturing in Microgravity

In an age where the boundaries between science fiction and reality are increasingly blurred, one venture stands out: the potential of in-orbit manufacturing (IOM). Set against the backdrop of the UK’s ambition to lead in space-enabled manufacturing, a pioneering start-up named BioOrbit is taking bold steps to reshape the pharmaceutical landscape by capitalizing on the unique environment of microgravity. In March 2026, BioOrbit plans to unveil a scalable in-orbit manufacturing system designed specifically for the crystallization of biologic drugs targeted at cancer treatment. This groundbreaking venture, part of a feasibility study funded by the UK Space Agency, exemplifies a collaborative effort involving multiple regulatory bodies, including the Medicines and Healthcare products Regulatory Agency (MHRA) and the Civil Aviation Authority (CAA).

The Microgravity Advantage

The microgravity environment presents unparalleled opportunities for pharmaceutical innovation. “In microgravity, we can manipulate the crystallization processes in ways we simply can’t achieve on Earth,” explains Dr. Elena Mirza, a prominent biochemist at Imperial College London. “This means that drugs can be manufactured with greater purity and efficacy, providing transformative solutions for patients.” Recent studies suggest that microgravity conditions enhance drug solubility and stability, thereby lowering manufacturing risks and costs.

This paradigm shift promises not only to advance precision medicines for conditions like oncology and rare diseases but also to create better solutions for crisis-affected populations. With the UK’s commitment to advancing innovative pharmaceutical manufacturing, there’s a strong focus on developing novel modalities that improve supply chain resilience and unlock new therapeutic possibilities. The goal is to ensure the highest standards of safety and regulatory compliance while fostering an environment that encourages innovators to explore cutting-edge biomanufacturing techniques.

Current Regulatory Framework

The regulatory landscape is evolving to accommodate the needs of this new frontier. The MHRA, which has garnered international acclaim for its innovative regulatory approaches, is at the forefront. Building on experiences from decentralized manufacturing frameworks introduced in 2025, the MHRA is collaborating with BioOrbit and the UK Space Agency to clarify how existing medicines regulations can apply to pharmaceuticals manufactured in space.

This collaborative endeavor aims to provide guidance for space biotech companies to navigate the complexities of whether terrestrial manufacturing regulations will extend to in-orbit pharmaceuticals. “We’re ensuring that the existing regulations remain fit for purpose, even in unique environments like microgravity,” says Dr. Samuel Leclerc, Head of Regulatory Innovation at the MHRA. “Our priority is to support innovation while safeguarding public health.”

• Funding Initiatives: The UK government is committed to funding diverse research projects, with a specific focus on in-orbit manufacturing technologies.
• Collaborative Workstreams: The MHRA and UK Space Agency are producing case studies that clearly delineate the licensing pathways for innovators.
• Regulatory Sandboxes: New guidance products and regulatory sandboxes are being developed to support the anticipated growth of in-orbit manufacturing activities.

The government’s flexible, outcome-focused approach to regulating spaceflight activities has already yielded successes. A notable example is Space Forge’s ForgeStar 1, which became the UK’s first licensed in-orbit manufacturing platform, successfully demonstrating the viability of this new technology. This initiative, closely monitored by the CAA, sets a precedent for future missions in the burgeoning field of in-orbit manufacturing.

Government Initiatives

The UK Space Agency is not just a passive observer; it’s actively working to secure the country’s position as a leader in this emerging field. “Our initiatives aim to provide the necessary support and clarity for the supply chain to adopt these cutting-edge technologies,” states Karen O’Brien, Senior Policy Advisor at the UK Space Agency. Recent interventions include:

• Engagement Workshops: The UK Space Agency is conducting workshops with the NHS and biopharma to understand barriers and stimulate demand.
• Literature Reviews: By examining past experiments conducted on the International Space Station, the UK is identifying its competitive advantages in biopharmaceutical development.
• Public-Private Dialogues: Events like the inaugural UK-Swiss Dialogue in June 2026 will bring together experts to tackle regulatory challenges and opportunities.

Through various funding programs, the UK is also working to bolster technological infrastructure and R&D capabilities. A significant £8 million investment in Cardiff, aimed at establishing a National Microgravity Research Centre, exemplifies this commitment. Such infrastructure will support collaborative research across institutions, fostering innovation in pharmaceuticals and beyond.

MHRA Collaboration

The collaborative spirit is evident in the way the MHRA is aligning its efforts with the UK Space Agency. This partnership is producing collaborative case studies that will clarify the regulatory landscape for developers and shine a light on the pathways to market for in-space manufactured pharmaceuticals.

“Our goal is to facilitate scientific and regulatory engagement,” notes Dr. Alison Chan, a senior regulatory scientist at the MHRA. “By providing developers early access to our guidance, we can ensure that their innovative ideas find the regulatory support they need.” This proactive approach is crucial in an era where rapid advancements often outpace existing frameworks, requiring regulatory bodies to think creatively.

The UK’s combined efforts signify a strong commitment not only to advancing space-enabled manufacturing but also to ensuring that the public health implications are carefully considered. The pathway to a thriving in-orbit pharmaceutical manufacturing industry is illuminated by collaboration, innovation, and a relentless pursuit of excellence.

Source: www.gov.uk